JB Chemicals On A Path Of Redefining Domestic Formulation: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
JB Chemicals and Pharmaceuticals Ltd. conducted its first analyst meet post KKR acquired 54% stake in CY20.
Guided for higher share of revenue from chronic portfolio in India formulation to 60% (versus 48% in nine-months FY21) in FY23E led by -
- new launches and foray in new therapy,
- prescription share gain in existing brands
- medical representative productivity improvement by 12-14% from current Rs 4.5 lakhs/month and
- 50% capex allocation towards Indian market.
The company also guided for an increase in its U.S. filing rate to five to six abbreviated new drug applications per year (from 1-2 ANDAs) along with launches of new brands in Russian market, however India formulations to remain key growth pillar.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.